Selegiline Pramipexole

DA agonists levodopa, bromocriptine, ropinirole, pramipexole, selegiline... 

DA agonists levodopa, bromocriptine, ropinirole, pramipexole, selegiline AAAD inhibitor carbidopa M-blockers benztropine, trihexiphenidyl MAOIs phenelzine, tranylcypromine TCAs amitriptyline, imipramine, clomipramine SSRIs fluoxetine, paroxetine, sertraline Others bupropion, mirtazapine, nefazodone, trazodone... 

A large number of molecules have provided experimental evidence of neuroprotection in in vitro and in vivo models of Parkinson s disease and many of these putative neuroprotective substances are now the objects of clinical trials. Recently, a team of experts has identified potential neuroprotective agents to be tested in pilot studies [4]. Twelve compounds have been considered for clinical trials caffeine, coenzyme Q 10, creatine, estrogen, GPI1485, GM-1 ganglioside, minocycline, nicotine, pramipexole, ropinirol, rasagiline, and selegiline (for individual discussion see [4]). 

Amantidine, bromocriptine, mazindol, pergolide, cabergoline, L-dopa/carbidopa, pramipexole, ABT-431, catecholamine metabolism inhibitors (disulfiram, phenelzine, selegiline), amineptine Methylphenidate, /-amphetamine, tropanes, GBR-12909 (partial agonist that may also act as antagonist), modafinil, coca tea... 

DOPAMINERGICS PARACETAMOL Amantadine, bromocriptine, levodopa, pergolide, pramipexole and selegiline may slow the onset of action of intermittent-dose paracetamol Anticholinergic effects delay gastric emptying and absorption Warn patients that the action of paracetamol may be delayed. This will not be the case when paracetamol is taken regularly... 

Drugs used to increase DA fundion are levodopa, tolcapone, entacapone, bromocriptine, pramipexole, ropinirole, and selegiline. Drugs that decrease ACh fundion are benztropine, trihexyphenidyl, and amantadine. The properties of each are described. 

Muscarinic receptor blockers may improve muscle rigidity and tremor in Parkinsons disease but result in very little improvement in bradykinesia thus, they are mainly considered as adjunctive to the use of drugs that improve dopaminergic function. Selegiline is the inhibitor of MAO type B, and pramipexole is a non-ergot DA receptor agonist. Carbidopa inhibits peripheral AAAD (dopa decarboxylase) tolcapone is an inhibitor of COMT. Levodopa causes a high incidence of dose-dependent dyskinesias that are not slow in onset, like tardive dyskinesia that results from chronic administration of DA receptor blockers. 

Another strategy is to directly enhance dopamine function as well as the activities of B-cell lymphoma protein 2 (Bcl-2), which is another important component that may play a role, eventually, in the resolution of depression. Examples of various non-selective enhancers of dopamine that also stimulate Bcl-2 are pergolide, ropinirole, and selegiline, while pramipexole may directly enhance Bcl-2. The antidepressant effect exhibited by enhanced dopaminergic transmission is thought to be at least partially related to increased dopaminergic transmission in limbic structures (e.g. the nucleus accumbens). - ... 

No significant pharmacokinetic interaction occurs between selegiline and cabei oline, pramipexole or ropinirole. 

The manufacturers of pramipexole say that no pharmacokinetic interaction occurs with selegiline. ... 

---